Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial
ML O'Donoghue, E Braunwald, HD White, DL Steen… - Jama, 2014 - jamanetwork.com
Importance Lipoprotein-associated phospholipase A 2 (Lp-PLA 2) has been hypothesized to
be involved in atherogenesis through pathways related to inflammation. Darapladib is an
oral, selective inhibitor of the Lp-PLA 2 enzyme. Objective To evaluate the efficacy and
safety of darapladib in patients after an acute coronary syndrome (ACS) event. Design,
Setting, and Participants SOLID-TIMI 52 was a multinational, double-blind, placebo-
controlled trial that randomized 13 026 participants within 30 days of hospitalization with an …
be involved in atherogenesis through pathways related to inflammation. Darapladib is an
oral, selective inhibitor of the Lp-PLA 2 enzyme. Objective To evaluate the efficacy and
safety of darapladib in patients after an acute coronary syndrome (ACS) event. Design,
Setting, and Participants SOLID-TIMI 52 was a multinational, double-blind, placebo-
controlled trial that randomized 13 026 participants within 30 days of hospitalization with an …